T cell engineering as a treatment for IgE-mediated allergy

The prevalence of allergies is on the rise in the Western world, and current treatment options are limited. Since IgE is a main player in the pathogenesis of many allergies, we sought to target IgE-producing B cells and abolish all IgE production. We redirected T cells using CAR potency of the cells and assessed against constructs to membrane-bound IgE on B cells. Additionally, we induced -6 target cells engineered to express mIgE-NALM class switching in human B cells, isolated from tonsils, to express mIgE, creating a more natural target for our T cells. Preliminary results show these CAR T cells effectively kill mIgEmediated -term therapeutic approach for IgE-expressing cells, indicating promising long-term effects on allergies.